Sign In
Sign In

What Is eCOA and Why Translation Matters

Electronic Clinical Outcome Assessment (eCOA) refers to the use of digital platforms to collect patient-centered data during clinical trials. eCOA tools replace traditional paper-based methods with electronic systems that improve data accuracy, streamline workflows, and enhance regulatory compliance. Effective implementation of eCOA in global trials requires accurate and culturally appropriate translation to ensure consistent patient experiences across languages and regions.

  • ePRO (electronic Patient-Reported Outcomes): Direct feedback from patients regarding their health status, symptoms, or treatment impact—entered electronically via tablets, smartphones, or web-based platforms.
  • ClinRO (Clinician-Reported Outcomes): Assessments made by clinicians based on professional observation and interaction with trial participants.
  • ObsRO (Observer-Reported Outcomes): Reports provided by third-party observers, such as caregivers or parents, typically used in pediatric or cognitively impaired populations.
  • PerfO (Performance Outcomes): Objective measures of participant performance on specific tasks, such as motor or cognitive function, administered and recorded electronically.

Accurate translation and linguistic validation are critical to the success of eCOA implementation in multilingual clinical trials:

  • Patient Usability: Translations must be simple, clear, and accessible to users of all literacy levels, ensuring intuitive navigation and accurate self-reporting.
  • Cultural Appropriateness: Language must reflect cultural norms and healthcare expectations, avoiding idioms or expressions that may not resonate or may introduce bias.
  • Regulatory Compliance: Regulatory agencies such as the FDA, EMA, and PMDA require rigorous linguistic validation for COA instruments to ensure conceptual equivalence and data reliability.
  • Data Integrity: Consistency in terminology and meaning across all languages preserves the scientific validity of trial data and supports global regulatory submissions.

Sesen specializes in providing high-quality eCOA translations that meet the linguistic, cultural, and regulatory demands of global clinical trials, helping sponsors and CROs deploy multilingual eCOA systems with confidence.

Our eCOA Translation Services

Sesen provides end-to-end eCOA translation solutions tailored for global clinical trials. Our services are designed to ensure linguistic accuracy, cultural appropriateness, and full regulatory compliance for electronic Patient-Reported Outcomes (ePRO), ClinROs, ObsROs, and PerfOs.

We conduct comprehensive linguistic validation following industry-standard methodologies to meet FDA, EMA, and PMDA expectations. Our process includes:

  • Dual forward translation
  • Reconciliation
  • Back translation
  • Expert review by medically qualified linguists
  • Cognitive debriefing with native-language participants
  • Finalization with documentation for regulatory submission

This rigorous workflow ensures conceptual equivalence, patient comprehension, and data reliability across all target languages. For a detailed discussion on Sesen’s professional linguistic validation solutions, please click here.

Beyond literal translation, we localize the user experience:

  • Patient-centric interface localization
  • Adaptation of language to reflect region-specific health literacy and cultural norms
  • Elimination of idioms or phrasing that may confuse or bias patient responses

This service supports higher eCOA engagement and improved data accuracy.

We localize audio and video content embedded within eCOA platforms—especially critical for ePRO applications with verbal instructions or visual task demonstrations. Services include:

  • Script translation
  • Voiceover recording in native languages
  • Subtitling and synchronization

All media is reviewed for clarity, tone, and alignment with patient demographics. For more information about Sesen’s comprehensive multimedia translation services, please click here.

Before translation begins, we assess source content to identify and resolve potential linguistic and cultural challenges. This preemptive step:

  • Enhances translatability
  • Ensures concept equivalence
  • Reduces the risk of costly revisions post-debriefing

Translatability assessments are especially important for newly developed COA instruments and study-specific adaptations.

Sesen partners directly with leading eCOA system providers, including:

  • Medidata
  • Veeva Vault ePRO
  • Signant Health
  • Clario (formerly ERT)
  • Kayentis
  • YPrime
  • TrialMaster

We align closely with vendor-specific workflows and formatting requirements to ensure seamless integration of localized content into eCOA platforms.

We provide all required documentation to support submission to global regulatory authorities:

  • Certified translation statements
  • Linguistic validation reports
  • Reviewer notes and debriefing summaries
  • Translatability assessment documentation

This complete audit trail simplifies sponsor submissions and reduces regulatory risk.

Why Sesen for eCOA Translation

Sesen delivers specialized eCOA translation services backed by deep life sciences expertise, regulatory-grade quality standards, and a proven track record in supporting global clinical trials. Here’s what sets us apart:

Our exclusive focus on the life sciences ensures subject matter precision across therapeutic areas, regulatory contexts, and clinical workflows—tailored for CROs, sponsors, and eCOA solution providers.

Sesen is fully ISO 17100 and ISO 9001:2015 certified, reflecting our commitment to rigorous quality management and professional translation practices in every project we deliver.

Each eCOA project is supported by a team of linguists with clinical trial expertise and dedicated project managers who coordinate timelines, workflows, and regulatory deliverables with precision.

We assign translators who are native in the target language and knowledgeable in the relevant therapeutic domain, ensuring terminological accuracy and cultural appropriateness for all patient and clinician-facing content.

Our validated workflows meet the linguistic validation and documentation standards required by major regulatory agencies for COA instrument translation and clinical trial submission.

We implement multi-level quality assurance, including automated checks, human review, and bilingual verification, to maintain translation integrity and consistency across all language versions.

Whether for a small study or a global Phase III trial, we scale resourcing to meet aggressive timelines without compromising on quality—supporting rapid deployment across multiple regions.

Sesen has successfully delivered eCOA localization for top CROs and global pharmaceutical companies, earning recognition for responsiveness, reliability, and clinical accuracy.

Our Translation Process for eCOA Projects

Sesen follows a validated, step-by-step translation process tailored to meet the rigorous linguistic, cultural, and regulatory requirements of eCOA instruments used in global clinical trials. Each stage is designed to ensure concept equivalence, patient comprehension, and full compliance with health authority standards.

Translatability Assessment

Before translation begins, we assess the source content to identify linguistic ambiguities, culturally sensitive phrases, or terminology that may not translate effectively. This step ensures optimal clarity, improves downstream accuracy, and reduces costly rework during validation.

Dual Forward Translation

Two independent, native-speaking linguists translate the source content into the target language. This dual-path approach allows us to compare interpretations and surface nuances that may impact the reliability of patient-reported outcomes.

Reconciliation

A senior reviewer consolidates the two forward translations into a single harmonized version, resolving any discrepancies while preserving the intent of the original instrument. This step ensures conceptual consistency and linguistic clarity.

Back Translation & Review

The reconciled version is translated back into the source language by a separate linguist with no prior exposure to the original text. Our reviewers compare this back translation to the original to confirm semantic accuracy and detect any unintended shifts in meaning.

Cognitive Debriefing with Native Participants

We conduct structured interviews with participants from the target population to assess comprehension, relevance, and ease of use. Feedback from this usability testing informs final revisions to ensure patient understanding and cultural appropriateness.

Finalization & Regulatory Documentation

Following any necessary updates, we prepare the final validated translation package, including:

  • Translation certificates
  • Linguistic validation reports
  • Cognitive debriefing summaries
  • Reviewer comments

These documents support submission to regulatory authorities such as the FDA, EMA, and PMDA.

In-App QA (if applicable)

For digital deployment, we perform in-context quality assurance within the eCOA platform—reviewing formatting, line breaks, UI layout, and language display to ensure functional accuracy across devices and languages.

Supported Therapeutic Areas

Sesen provides eCOA translation and linguistic validation services across a wide range of therapeutic areas commonly used in global clinical trials. Our specialized linguists have domain-specific knowledge and experience adapting Clinical Outcome Assessments (COAs) to meet patient, clinician, and regulatory expectations across diverse indications.

We have supported ePRO, ClinRO, ObsRO, and PerfO instrument localization in the following key areas:

Translation of cancer-related eCOA instruments including symptom tracking, quality of life (QoL), fatigue, and treatment impact scales across solid tumors and hematologic malignancies.

Localization of assessments for neurological disorders such as Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, and epilepsy, with emphasis on cognitive, motor, and emotional function measures.

eCOA support for clinical trials involving depression, anxiety, bipolar disorder, schizophrenia, and sleep disorders. Our team ensures accurate translation of psychiatric rating scales and patient-reported mental health metrics.

Expertise in adapting eCOA instruments for small and geographically dispersed patient populations with ultra-rare or orphan conditions, including high-sensitivity translations for novel instruments.

Translation and validation of ePRO and ClinRO tools used in antiviral, antimicrobial, and vaccine trials, including studies involving COVID-19, HIV, hepatitis, and respiratory infections.

Linguistic validation of pain intensity scales, diaries, and functional assessments used in both acute and chronic pain studies, including complex conditions such as fibromyalgia or neuropathic pain.

Specialized support for age-appropriate translation of eCOA content for children and adolescents, including ObsRO and PedsQL instruments, tailored for cognitive and developmental stages.

Our deep therapeutic area experience ensures that translations maintain medical accuracy, cultural sensitivity, and regulatory-grade validation—empowering sponsors and CROs to deploy patient-facing eCOA instruments across global study populations with confidence.

eCOA Systems We Support

Sesen partners with leading eCOA technology providers to deliver seamless, end-to-end translation and localization services tailored to platform-specific requirements. Our team has extensive experience working within diverse digital ecosystems, ensuring that all translated content is properly formatted, contextually accurate, and deployment-ready across global study sites.

We support eCOA integration and localization for the following systems:

Expertise in translating eCOA instruments for Medidata’s Rave eCOA platform, including in-app content, patient notifications, and instructional modules.

End-to-end language support for sponsors and CROs using Veeva Vault ePRO, including translation of assessments, system prompts, and compliance-related messaging.

Proven experience localizing content within Signant Health’s eCOA and ePRO systems—formerly CRF Health and Bracket—with full support for linguistic validation and usability testing.

Technical familiarity with Clario’s eCOA technology for clinical endpoints, supporting localization of text, audio, and multimedia instructions for both patients and site staff.

Seamless integration of localized content into Kayentis Clin’form eCOA platform, including therapeutic-area specific instruments and pediatric adaptations.

Translation and formatting support for sponsors using TrialMaster ePRO and EDC tools, ensuring consistency across eCRFs and COA modules.

Support for eCOA instrument deployment within Castor EDC, including localization of patient-facing content and clinician assessment forms in multilingual clinical trials.

Our familiarity with these platforms allows us to streamline localization workflows, reduce technical friction, and maintain the integrity of translated content across devices, operating systems, and regulatory frameworks.

Example: How Sesen Approaches eCOA Translation

The following sample demonstrates how Sesen translates and validates electronic Clinical Outcome Assessment (eCOA) instruments for global clinical trials. While the study and product names are fictitious, the process reflects real-world workflows and industry best practices used to ensure linguistic accuracy, cultural appropriateness, and regulatory compliance.

Sample ePRO Instrument Translation

Study Name: NPX-102 Phase III Global Trial

Sponsor: NeoPharmica Inc. (fictional)

Instrument Name: Treatment Side Effect Diary

Language Pair: English to Spanish (Spain) & German (Germany)

Assessment Type: ePRO – Daily Symptom Diary

All product names, organization names, and content presented here are fictitious and provided for illustration purposes only.

Sample ePRO Item – Source (English)

Item ID

Source Text

SE01

In the past 24 hours, how often did you feel nauseated after taking the study medication?

Response Options:

Never / Rarely / Sometimes / Often / Always

Translated Versions

Spanish (Spain)

  • Question: En las últimas 24 horas, ¿con qué frecuencia sintió náuseas después de tomar la medicación del estudio?
  • Responses: Nunca / Rara vez / A veces / A menudo / Siempre

German (Germany)

  • Question: Wie häufig haben Sie sich in den letzten 24 Stunden nach der Einnahme des Prüfmedikaments übel gefühlt?
  • Responses: Nie / Selten / Manchmal / Oft / Immer

Linguistic Validation Snapshot

Step

Description

Translatability Assessment

The source question was assessed for clarity and cultural neutrality. No changes were recommended prior to translation.

Dual Forward Translations

Two native linguists provided independent translations, highlighting nuances between “felt nauseated” and “experience of nausea.”

Reconciliation

A senior reviewer selected “sentir náuseas” in Spanish and “übel gefühlt” in German for better patient comprehension and conceptual alignment.

Back Translation

Spanish: “In the last 24 hours, how often did you feel nauseous after taking the study medicine?”

 

German: “In the last 24 hours, how often did you feel nauseous after taking the trial medication?”

 

Both were validated against the source and found to be semantically equivalent.

Cognitive Debriefing

Conducted with 5 native Spanish and 5 native German speakers. Participants found the question and response scale clear and appropriate. Minor formatting adjustments were applied.

Finalization

Approved translations were locked for integration into the Medidata eCOA platform. Certification of Translation and validation report issued.

In-App UI Preview (Fictional Layout)

Device: Tablet | Language: Spanish

Title: Registro de efectos secundarios

Pregunta 1:
En las últimas 24 horas, ¿con qué frecuencia sintió náuseas después de tomar la medicación del estudio?

◯ Nunca
◯ Rara vez
◯ A veces
◯ A menudo
◯ Siempre

Let me know if you’d like this styled as a downloadable PDF for client use, or designed visually for web display with UI mockups and icons.

Frequently Asked Questions (FAQ)

eCOA (electronic Clinical Outcome Assessment) is an umbrella term that includes various types of clinical trial assessments captured electronically—such as ePRO, ClinRO, ObsRO, and PerfO.
ePRO (electronic Patient-Reported Outcomes) is a specific type of eCOA that collects direct input from patients about their symptoms, health status, or treatment experience via digital devices.

Sesen supports eCOA translation in over 150 languages, covering all major global markets and regional dialects. We provide native-language linguists with therapeutic area expertise to ensure cultural and regulatory alignment across multilingual studies.

Timelines vary depending on the number of languages, type of COA instrument, and whether linguistic validation is required.
A standard eCOA translation and validation project typically takes 4 to 8 weeks, including translatability assessment, dual forward translation, back translation, cognitive debriefing, and finalization. Expedited timelines are available upon request.

Yes. Sesen offers full cognitive debriefing services with native-speaking participants from the target population to assess clarity, comprehension, and cultural relevance. We also support usability testing for digital ePRO platforms to ensure accurate patient interaction across devices and languages.

Sesen follows validated linguistic workflows that meet regulatory guidelines for Clinical Outcome Assessment (COA) translation and validation. We provide comprehensive documentation—including translation certificates, validation reports, and cognitive debriefing summaries—to support submissions to global health authorities such as the FDA, EMA, and PMDA.

Client Testimonials & Success Stories

Sesen is trusted by leading CROs and pharmaceutical sponsors for fast, accurate, and regulatory-compliant eCOA translation services. Our proven track record reflects our commitment to quality, responsiveness, and domain expertise in global clinical trials.

“Sesen helped us localize ePRO instruments in eight languages with full linguistic validation—including cognitive debriefing and regulatory documentation—delivered in under six weeks. Their team was proactive, detail-oriented, and deeply knowledgeable about eCOA workflows.”

— Senior Clinical Operations Manager, Global CRO

Ready to Translate Your eCOA Instruments?

Partner with Sesen to ensure your eCOA content is accurately translated, culturally adapted, and fully validated for global clinical trials. Whether you need support for a single study or a multi-region rollout, our team is ready to help.

REQUEST A CONSULTATION REQUEST A CONSULTATION
SUBMIT YOUR RFP SUBMIT YOUR RFP